What is BioCardia?
BioCardia operates at the intersection of biotechnology and cardiology, specializing in regenerative medicine solutions designed to address critical unmet medical needs. The company's core value proposition centers on its CardiAMP and CardiALLO platforms, which utilize advanced intramyocardial delivery of marrow-derived cells. By focusing on rigorous clinical data and proprietary delivery systems, BioCardia distinguishes itself as a leader in the development of novel therapeutics for heart disease. Its market position is defined by a commitment to evidence-based medicine, aiming to transform standard care protocols through innovative cellular therapies that target the underlying pathology of cardiovascular conditions.
How much funding has BioCardia raised?
BioCardia has raised a total of $8.8M across 2 funding rounds:
Debt
$4.4M
Stock/Share Issuance
$4.4M
Debt (2016): $4.4M, investors not publicly disclosed
Stock/Share Issuance (2026): $4.4M, investors not publicly disclosed
Key Investors in BioCardia
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for BioCardia?
With this major enterprise-level funding, BioCardia is positioned to scale its clinical operations and refine its biotherapeutic delivery mechanisms. The strategic roadmap likely involves expanding patient enrollment in pivotal trials and strengthening the regulatory pathway for its lead candidates. As the firm transitions from early-stage development to more advanced clinical milestones, the focus will remain on demonstrating long-term efficacy and safety. Investors and stakeholders will be monitoring the company's ability to translate its compelling preliminary data into scalable, market-ready solutions that address the global burden of cardiovascular disease, potentially setting a new benchmark for regenerative medicine in the clinical sector.
See full BioCardia company page
